终末期肾病抗血栓治疗的利弊:2019年更新
透析患者同时存在血栓和出血风险,常合并心血管疾病需抗血栓治疗,但随机对照试验极少,指南推荐不明确。欧洲透析工作组综述观察性研究证据,讨论抗血小板和抗凝药物单用或联用的利弊,强调治疗目标为最小化血栓风险同时减少出血事件。
要点
- 透析患者血栓和出血风险并存,抗血栓决策需个体化平衡。
- 缺乏随机对照试验,指南推荐不明确且常排除透析患者。
- 治疗目标为最小化血栓风险同时减少出血事件。
核心结论
- 透析患者抗血栓治疗需权衡血栓与出血风险,目前证据多来自观察性研究,亟需专家共识指导决策。
研究设计与样本
- 欧洲透析工作组综述,基于观察性研究证据讨论抗血小板和抗凝药物单用或联用的利弊。
主要发现
- 透析患者心血管合并症(冠心病、房颤或静脉血栓栓塞)常见,抗血栓治疗指征多样。
- 随机对照试验极少,指南推荐不明确,常排除或忽略透析患者。
- 观察性研究提供支持或反对使用抗血小板和抗凝药物的数据。
临床怎么用
- 在缺乏明确证据时,医生应根据观察性研究数据选择替代方案,以限制出血并最小化动脉粥样硬化血栓和心源性栓塞风险。
局限性
- 缺乏随机对照试验,证据主要来自观察性研究,指南推荐不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dialysis patients manifest both an increased thrombotic risk and a haemorrhagic tendency. A great number of patients with chronic kidney disease requiring dialysis have cardiovascular comorbidities (coronary artery disease, atrial fibrillation or venous thromboembolism) and different indications for treatment with antithrombotics (primary or secondary prevention). Unfortunately, few randomized controlled trials deal with antiplatelet and/or anticoagulant therapy in dialysis. Therefore cardiology and nephrology guidelines offer ambiguous recommendations and often exclude or ignore these patients. In our opinion, there is a need for an expert consensus that provides physicians with useful information to make correct decisions in different situations requiring antithrombotics. Herein the European Dialysis Working Group presents up-to-date evidence about the topic and encourages practitioners to choose among alternatives in order to limit bleeding and minimize atherothrombotic and cardioembolic risks. In the absence of clear evidence, these clinical settings and consequent therapeutic strategies will be discussed by highlighting data from observational studies for and against the use of antiplatelet and anticoagulant drugs alone or in combination. Until new studies shed light on unclear clinical situations, one should keep in mind that the objective of treatment is to minimize thrombotic risk while reducing bleeding events.
引用
- Burlacu A, Genovesi S, Ortiz A, et al. Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. Nephrol Dial Transplant. 2019. PMID: 30879070. doi:10.1093/ndt/gfz040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。